Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBOT NASDAQ:NTRB NASDAQ:STIM NASDAQ:VANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBOTMicrobot Medical$1.79-3.8%$1.87$1.60▼$4.67$124.93M1.04695,219 shs999,964 shsNTRBNutriband$3.13+2.6%$3.33$2.90▼$9.21$37.08M1.9314,176 shs23,683 shsSTIMNeuronetics$1.78-3.3%$1.39$0.80▼$4.85$128.04M1.061.26 million shs11.81 million shsVANIVivani Medical$1.35-4.3%$1.24$0.92▼$1.92$121.59M2.331.02 million shs649,470 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBOTMicrobot Medical-3.76%-3.76%-1.65%-23.50%-29.80%NTRBNutriband+2.62%+1.29%-5.44%-27.21%-61.45%STIMNeuronetics-3.26%+7.23%+48.33%+25.35%-50.56%VANIVivani Medical-4.26%-13.46%+15.38%+0.75%-16.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBOTMicrobot Medical$1.79-3.8%$1.87$1.60▼$4.67$124.93M1.04695,219 shs999,964 shsNTRBNutriband$3.13+2.6%$3.33$2.90▼$9.21$37.08M1.9314,176 shs23,683 shsSTIMNeuronetics$1.78-3.3%$1.39$0.80▼$4.85$128.04M1.061.26 million shs11.81 million shsVANIVivani Medical$1.35-4.3%$1.24$0.92▼$1.92$121.59M2.331.02 million shs649,470 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBOTMicrobot Medical-3.76%-3.76%-1.65%-23.50%-29.80%NTRBNutriband+2.62%+1.29%-5.44%-27.21%-61.45%STIMNeuronetics-3.26%+7.23%+48.33%+25.35%-50.56%VANIVivani Medical-4.26%-13.46%+15.38%+0.75%-16.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBOTMicrobot Medical 2.60Moderate Buy$6.63270.11% UpsideNTRBNutriband 1.50ReduceN/AN/ASTIMNeuronetics 2.00Hold$3.0068.54% UpsideVANIVivani Medical 2.25Hold$3.75177.78% UpsideCurrent Analyst Ratings BreakdownLatest NTRB, MBOT, STIM, and VANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026MBOTMicrobot Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/8/2026MBOTMicrobot Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/7/2026VANIVivani Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/1/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/23/2026VANIVivani Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/23/2026VANIVivani Medical Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.006/23/2026VANIVivani Medical Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.006/18/2026STIMNeuronetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/17/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/9/2026VANIVivani Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/3/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBOTMicrobot MedicalN/AN/AN/AN/A$1.15 per shareN/ANTRBNutriband$2.04M18.66N/AN/A$0.55 per share5.69STIMNeuronetics$149.16M0.83N/AN/A$0.38 per share4.68VANIVivani MedicalN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBOTMicrobot Medical-$13.14M-$0.26N/AN/AN/AN/A-21.84%-20.71%8/11/2026 (Estimated)NTRBNutriband-$8.23M-$2.58N/AN/AN/A-448.25%-112.64%-97.86%N/ASTIMNeuronetics-$39M-$0.54N/AN/AN/A-24.48%-139.83%-27.13%8/4/2026 (Estimated)VANIVivani Medical-$26.61M-$0.40N/AN/AN/AN/A-264.04%-79.85%8/12/2026 (Estimated)Latest NTRB, MBOT, STIM, and VANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026VANIVivani Medical-$0.08N/AN/AN/AN/AN/A8/11/2026Q2 2026MBOTMicrobot Medical-$0.08N/AN/AN/A$0.33 millionN/A8/4/2026Q2 2026STIMNeuronetics-$0.11N/AN/AN/A$40.09 millionN/A6/11/2026Q1 2027NTRBNutribandN/A-$0.10N/A-$0.10N/A$0.43 million5/13/2026Q1 2026MBOTMicrobot Medical-$0.08-$0.05+$0.03-$0.05$0.30 million$0.11 million5/13/2026Q1 2026VANIVivani Medical-$0.08-$0.08N/A-$0.08N/AN/A5/5/2026Q1 2026STIMNeuronetics-$0.17-$0.16+$0.01-$0.16$34.17 million$34.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMBOTMicrobot MedicalN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBOTMicrobot Medical0.0122.5921.93NTRBNutribandN/A5.265.11STIMNeuronetics3.591.671.50VANIVivani MedicalN/A3.183.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBOTMicrobot Medical16.30%NTRBNutriband19.70%STIMNeuronetics53.59%VANIVivani Medical6.78%Insider OwnershipCompanyInsider OwnershipMBOTMicrobot Medical4.74%NTRBNutriband52.21%STIMNeuronetics8.40%VANIVivani Medical53.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBOTMicrobot Medical2067.17 million63.98 millionOptionableNTRBNutriband1012.16 million5.81 millionNot OptionableSTIMNeuronetics18069.59 million63.74 millionOptionableVANIVivani Medical2086.24 million40.27 millionOptionableNTRB, MBOT, STIM, and VANI HeadlinesRecent News About These CompaniesVivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk DealJuly 15 at 7:01 PM | marketbeat.comVivani Medical to Present at the Emerging Growth Conference on July 15, 2026July 14 at 4:03 PM | globenewswire.comNext Frontier In Weight Loss? New Implant Looks To Lock In GLP-1 ResultsJuly 14 at 8:19 AM | msn.comThe next GLP-1 bet? Implant draws Novo interestJuly 13, 2026 | beckershospitalreview.comBVivani MedicalJuly 13, 2026 | fool.comWeight-loss implant could one day replace Ozempic injectionsJuly 12, 2026 | msn.comAnalysts Set Expectations for Vivani Medical Q1 EarningsJuly 10, 2026 | marketbeat.comNovo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani DealJuly 9, 2026 | finance.yahoo.comVivani Medical signs agreement with Novo Nordisk to evaluate NPM-139July 9, 2026 | pharmabiz.comPOzempic & Wegovy maker to evaluate long-acting GLP-1 implant that could last up to a yearJuly 9, 2026 | msn.comNovo Nordisk pens long-acting GLP-1 implant tech deal with Vivani MedicalJuly 7, 2026 | fiercebiotech.comFNovo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide ImplantJuly 7, 2026 | finance.yahoo.comVivani Medical (NASDAQ:VANI) versus Biostar Pharmaceuticals (OTCMKTS:BSPM) Critical SurveyJuly 7, 2026 | americanbankingnews.comVivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight ManagementJuly 7, 2026 | globenewswire.comVivani strikes reverse-merger agreement with ClearOne for BCI businessJuly 3, 2026 | finance.yahoo.comClearOne to Merge With Vivani Medical Subsidiary CortigentJuly 2, 2026 | marketwatch.comVivani to sell neurotech subsidiary Cortigent to ClearOneJuly 2, 2026 | massdevice.comClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani MedicalJuly 2, 2026 | businesswire.comVivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.July 2, 2026 | globenewswire.comVivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement ...June 26, 2026 | caledonianrecord.comCVivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean BakerJune 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNextEra’s Dominion Deal Could Put It at the Center of the AI Power RaceBy Nathan Reiff | June 30, 2026General Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsBy Thomas Hughes | July 2, 2026Investors Are Buying Into Sweetgreen Again—Should They?By Jennifer Ryan Woods | June 22, 2026BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneBy Chris Markoch | June 26, 2026SpaceX Achieves Escape Velocity With Nasdaq Fast-TrackBy Jeffrey Neal Johnson | June 30, 2026NTRB, MBOT, STIM, and VANI Company DescriptionsMicrobot Medical NASDAQ:MBOT$1.79 -0.07 (-3.76%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$1.78 -0.02 (-0.84%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Nutriband NASDAQ:NTRB$3.13 +0.08 (+2.62%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$3.10 -0.03 (-0.93%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Neuronetics NASDAQ:STIM$1.78 -0.06 (-3.26%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$1.88 +0.10 (+5.34%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Vivani Medical NASDAQ:VANI$1.35 -0.06 (-4.26%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.85%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
